A Standardised Protocol for Assessment of Relative SARS-CoV-2 Variant Severity, with Application to Severity Risk for COVID-19 Cases Infected with Omicron BA.1 Compared to Delta Variants in six European Countries
Tommy Nyberg(University of Cambridge), Anne M. Presanis(University of Cambridge), Joël Mossong(Luxembourg Institute of Health), Lamprini Veneti(Norwegian Institute of Public Health), Simon Thelwall(UK Health Security Agency), Josie Evans(Public Health Scotland), Heather Mutch(Government of the United Kingdom), Peter Bager(Statens Serum Institut), Ajibola Omokanye(European Centre for Disease Prevention and Control), Tyra Grove Krause(Statens Serum Institut), Pedro Pinto Leite(Direção Geral do Território), Jostein Starrfelt(Norwegian Institute of Public Health), Nick Bundle(European Centre for Disease Prevention and Control), Dritan Bejko(Luxembourg Institute of Health), André Peralta‐Santos(Direção Geral do Território), Richard Pebody(National Security Agency), Robert Whittaker(Norwegian Institute of Public Health), Ingrid Bech Svalgaard(Statens Serum Institut), John Wood(Institute of High Energy Physics), Jim McMenamin(Public Health Scotland)
Cited by 1
Related Papers
Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases
|PLoS Medicine|2008|3.2k
First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020
|Eurosurveillance|2020|715
Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies
|PLoS Medicine|2022|298
Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008
|Eurosurveillance|2008|286